A Booster Study of S-268019 in Japan (COVID-19)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2021
INTERVENTION: S‐268019 or COMIRNATY (intramuscular injection) CONDITION: Prevention of COVID‐19 PRIMARY OUTCOME: SARS‐CoV‐2 neutralizing antibody titer on Day 29 INCLUSION CRITERIA: Participant must be >= 20 years of age inclusive, at the time of signing the informed consent. Participant who have received 2 doses of COMIRNATY and at least 6 months post second dose.
Epistemonikos ID: eaf685b0387279c984753dca839fb156d0c770ab
First added on: Aug 25, 2024